These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22231078)

  • 1. Russian fund steps up investments in innovative biotechs.
    Katsnelson A
    Nat Biotechnol; 2012 Jan; 30(1):9-11. PubMed ID: 22231078
    [No Abstract]   [Full Text] [Related]  

  • 2. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 3. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 5. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 6. Investors likely to venture back as crisis subsides.
    Glick JL
    Nature; 2009 Aug; 460(7259):1079. PubMed ID: 19713912
    [No Abstract]   [Full Text] [Related]  

  • 7. Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
    McLean B
    Fortune; 2000 Jan; 141(1):132-4, 135. PubMed ID: 10788044
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotechs feel the pain.
    Ledford H
    Nature; 2009 Jan; 457(7226):136-7. PubMed ID: 19129814
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 10. Commercializing nanotechnology.
    Mazzola L
    Nat Biotechnol; 2003 Oct; 21(10):1137-43. PubMed ID: 14520392
    [No Abstract]   [Full Text] [Related]  

  • 11. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 12. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 13. Gary Pisano.
    Pisano G
    Nat Biotechnol; 2011 Mar; 29(3):183. PubMed ID: 21390002
    [No Abstract]   [Full Text] [Related]  

  • 14. Stelios Papadopoulos.
    Papadopoulos S
    Nat Biotechnol; 2011 Mar; 29(3):184. PubMed ID: 21390003
    [No Abstract]   [Full Text] [Related]  

  • 15. Paul Keckley.
    Keckley P
    Nat Biotechnol; 2011 Mar; 29(3):185. PubMed ID: 21390004
    [No Abstract]   [Full Text] [Related]  

  • 16. A special biotech speculation.
    Jacobs T
    Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
    [No Abstract]   [Full Text] [Related]  

  • 17. Finding new life in health stocks.
    Armour LA
    Fortune; 1997 Sep; 136(6):289-90, 292, 294. PubMed ID: 10173398
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 19. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 20. No pain, no gain?
    Jacobs T
    Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.